Adjunctive Rifampicin Increases Antibiotic Efficacy in Group A Streptococcal Tissue Infection Models-Reference-Cited by-同舟云学术

Adjunctive Rifampicin Increases Antibiotic Efficacy in Group A Streptococcal Tissue Infection Models

Published:2021-10-18 Issue:11 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Bergsten H.¹,Palma Medina L. M.¹,Morgan M.²,Moll K.¹,Skutlaberg D. H.³⁴,Skrede S.⁴⁵,Wajima T.⁶^ORCID,Svensson M.¹,Norrby-Teglund A.¹^ORCID

Affiliation:

1. Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

2. Royal Devon and Exeter Hospital, Exeter, United Kingdom

3. Department of Microbiology, Haukeland University Hospital, Bergen, Norway

4. Department of Clinical Science, University of Bergen, Bergen, Norway

5. Department of Medicine, Haukeland University Hospital, Bergen, Norway

6. Department of Microbiology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan

Abstract

Biofilm has recently been highlighted as a complicating feature of necrotizing soft tissue infections (NSTI) caused by Streptococcus pyogenes (i.e., group A Streptococcus [GAS]) contributing to a persistence of bacteria in tissue despite prolonged antibiotic therapy. Here, we assessed the standard treatment of benzylpenicillin and clindamycin with or without rifampin in a tissue-like setting.

Funder

Center for Innovative Medicine and Region Stockholm

Swedish Research Council

Norges Forskningsråd

Swedish Governmental Agency for Innovation Systems Vinnova

Karolinska Institutet

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00658-21